Company intelligence / Profile preview

PCI Biotech

Ownership: Public · PCIB
Development stage: Phase 2

Overview

PCI Biotech has developed a proprietary photochemical platform for targeted intracellular drug delivery. The company’s lead programs have demonstrated strong anti-tumor responses in early-phase clinical trials. Recent efforts are focused on improving viral vector manufacturing via photochemical lysis and enhancing the efficacy of immunotherapies and nucleic acid drugs through improved cellular uptake.

Therapeutic areas: OncologyDermatology
Modalities: Small molecule (photosensitiser)Nucleic acid therapeuticsImmunotherapy (including T-cell induction technology)
Industry: Biotech

Drug pipeline

4 assets

fimaporfin

3 more assets in the full pipeline.

Request access →

Partnerships

Member of Oslo Cancer Cluster

Financials

Market cap: $140.2M
Total revenue: $230.5M

Beyond the preview

Go deeper on PCI Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCI Biotech.

Explore the full profile